Fenwick & West represented Seattle Genetics, Inc. (NASDAQ: SGEN), in an immuno-oncology collaboration with Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Through this collaboration, the companies will pair their respective technologies to develop new immuno-oncology treatments for solid tumors and blood cancers.

The Fenwick transaction team was led by Stefano Quintini with support from technology transaction lawyer Amy Manning and antitrust partner Mark Ostrau.

Login

Don’t have an account yet?

Register